Skip to search formSkip to main contentSkip to account menu

trametinib

Known as: N-(3-{3-cyclopropyl-5-[(2-fluoro-4-iodophenyl)amino]-6,8-dimethyl-2,4,7-trioxo-3,4,6,7-tetrahydropyrido[4,3-d]pyrimidin-1(2H)-yl}phenyl)acetamide, Trametinibum 
An orally bioavailable inhibitor of mitogen-activated protein kinase kinase (MEK MAPK/ERK kinase) with potential antineoplastic activity. Trametinib… 
National Institutes of Health

Related topics

Related topics

11 relations

Broader (4)

Antineoplastic AgentsProtein Kinase InhibitorsPyridonesPyrimidinones

Narrower (4)

GSK 1120212JTP 74057Mekinisttrametinib dimethyl sulfoxide
NCIt Antineoplastic Agent Terminologytrametinib 2 MG Oral Tablettrametinib 2 MG Oral Tablet [Mekinist]

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
2018
2018
Preliminary findings from part 1 of COMBI-i: A phase III study of anti–PD-1 antibody PDR001 combined with dabrafenib (D) and trametinib (T) in previously untreated patients (pts) with advanced BRAF…
189Background: Checkpoint inhibitors and targeted therapies have improved outcomes in pts with advanced BRAF V600–mutant melanoma… 
2017
2017
Synergistic effect of MEK inhibitor and metformin combination in low grade serous ovarian cancer.
2017
2017
Combined blockade of Tim-3 and MEK inhibitor enhances the efficacy against melanoma.
Highly Cited
2016
Highly Cited
2016
Genomic analysis and 3-y efficacy and safety update of COMBI-d: A phase 3 study of dabrafenib (D) + trametinib (T) vs D monotherapy in patients (pts) with unresectable or metastatic BRAF V600E/K…
9502Background: Previous analysis of COMBI-d (NCT01584648) showed that D+T compared with D monotherapy improved ORR (69% [95% CI… 
Review
2016
Review
2016
The Systemic Management of Advanced Melanoma in 2016
Melanoma is a common type of skin cancer with a high propensity to metastasize. Tyrosine kinase inhibitors targeting the mitogen… 
Highly Cited
2014
Highly Cited
2014
BRAF inhibitors in cancer therapy.
Highly Cited
2014
Highly Cited
2014
Phase 1 study of the BRAF inhibitor dabrafenib (D) with or without the MEK inhibitor trametinib (T) in combination with ipilimumab (Ipi) for V600E/K mutation–positive unresectable or metastatic…
2511 Background: D, T, and Ipi are each indicated for treatment of patients (pts) with MM (D+T in BRAF V600 mutation–positive MM… 
2014
2014
COX‐2 inhibition prevents the appearance of cutaneous squamous cell carcinomas accelerated by BRAF inhibitors
Review
2014
Review
2014
New developments in the treatment of metastatic melanoma: immune checkpoint inhibitors and targeted therapies.
The incidence of melanoma has been increasing over the past twenty years. Unfortunately, the prognosis of advanced-stage disease… 
2014
2014
Cutaneous granulomatous eruption and successful response to potent topical steroids in patients undergoing targeted BRAF inhibitor treatment for metastatic melanoma.
IMPORTANCE Targeted BRAF inhibitor therapy (vemurafenib, dabrafenib) is an effective, novel treatment for patients with… 
By clicking accept or continuing to use the site, you agree to the terms outlined in our Privacy Policy (opens in a new tab), Terms of Service (opens in a new tab), and Dataset License (opens in a new tab)